Neurotoxicity of Tumor Immunotherapy: The Emergence of Clinical Attention

Benxia Zhang; Xue Li; Tao Yin; Diyuan Qin; Yue Chen; Qizhi Ma; Pei Shu; Yongsheng Wang

doi:10.1155/2022/4259205

Neurotoxicity of Tumor Immunotherapy: The Emergence of Clinical Attention

J Oncol. 2022 Jan 18:2022:4259205. doi: 10.1155/2022/4259205. eCollection 2022.

Authors

Benxia Zhang^{1

2}, Xue Li^{1

2}, Tao Yin^{1

2}, Diyuan Qin^{1

2}, Yue Chen^{1

2}, Qizhi Ma^{1

2}, Pei Shu^{1

2}, Yongsheng Wang^{1

2}

Affiliations

¹ Clinical Trial Center, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
² Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Abstract

Tumor immunotherapy brings substantial and long-term clinical benefits that can even cure tumors. However, the accumulation of evidence suggests that immunotherapy also induces severe and complex neurologic immune-related adverse events (ir-AEs) and even leads to immunotherapy-related death, which arouses the concern of clinicians. The timely and accurate identification of neurotoxicity helps clinicians detect and treat these complications early, thereby enhancing treatment efficiency and improving the prognosis of patients. At present, the mechanism of neurotoxicity caused by immunotherapy has not been completely elucidated. This paper mainly reviews the clinical features, pathogenesis, and therapeutic strategies of neurologic ir-AEs.

Publication types

Review